Are you or a loved one currently facing advanced pancreatic cancer? Stand Up To Cancer (SU2C) is supporting a clinical trial that may benefit patients with advanced pancreatic cancer and make dramatic gains for patient outcomes for this deadly disease.
What is immunotherapy?
The use of medicines to stimulate a person’s own immune system to recognize and destroy cancer cells more effectively.
Immunotherapies have shown benefits across a range of human cancers, but so far have not worked well in pancreatic cancer patients. Recent evidence suggests that one major roadblock for the effective use of immunotherapies in pancreatic cancer patients is that the tumors are effectively hidden, preventing the immune system from recognizing and killing them. Research from our team suggests that therapies targeting the vitamin D receptor will perhaps “unmask” the pancreatic tumors and allow the immune cells to reach them, creating the possibility that immunotherapies will be effective.
The goal of this clinical trial is to test if targeting the vitamin D receptor will unlock the potential of immunotherapies to kill pancreatic cancer tumor cells and potentially establish a therapeutic combination for controlling advanced pancreatic cancer, extending patient survival, and reducing patient side effects. Additionally, we hope to identify features that drive patient responses to immunotherapy and gain insight into additional strategies for converting immunotherapy resistant tumors into tumors that
respond to treatment.